For example, ibrutinib combined with PD-1/PD-L1 blockade enhances the activity of CD8 T cells and regulates lymphocyte proliferation, offering a potent treatment strategy for CLL and other cancers [115]. This evidence concerns the gene PDCD1 and cancer.